Immunome, Inc. (NASDAQ:IMNM) Receives $31.00 Average Price Target from Analysts

Shares of Immunome, Inc. (NASDAQ:IMNM) have been assigned a consensus rating of “Moderate Buy” from the eleven analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $31.00.

A number of equities research analysts have recently issued reports on IMNM shares. Lake Street Capital boosted their price target on shares of Immunome from $22.00 to $32.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. Evercore ISI raised their price target on shares of Immunome from $18.00 to $40.00 and gave the stock an “outperform” rating in a report on Tuesday, December 16th. Wall Street Zen upgraded Immunome from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. Leerink Partners set a $40.00 price target on Immunome in a research note on Monday, December 15th. Finally, Wedbush reissued an “outperform” rating and set a $31.00 target price on shares of Immunome in a research report on Thursday, January 15th.

Insiders Place Their Bets

In other Immunome news, CEO Clay B. Siegall purchased 46,511 shares of the business’s stock in a transaction dated Thursday, December 18th. The stock was bought at an average cost of $21.50 per share, for a total transaction of $999,986.50. Following the completion of the acquisition, the chief executive officer directly owned 853,247 shares in the company, valued at $18,344,810.50. This represents a 5.77% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Philip Tsai purchased 10,000 shares of the firm’s stock in a transaction on Friday, December 19th. The stock was bought at an average price of $20.49 per share, for a total transaction of $204,900.00. Following the completion of the transaction, the insider directly owned 43,300 shares in the company, valued at approximately $887,217. The trade was a 30.03% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 68,518 shares of company stock valued at $1,453,958 in the last three months. Company insiders own 7.69% of the company’s stock.

Hedge Funds Weigh In On Immunome

Several hedge funds and other institutional investors have recently modified their holdings of IMNM. Vanguard Group Inc. increased its position in shares of Immunome by 23.4% during the 4th quarter. Vanguard Group Inc. now owns 6,038,414 shares of the company’s stock worth $129,705,000 after purchasing an additional 1,144,788 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Immunome by 6.7% in the second quarter. Geode Capital Management LLC now owns 1,860,580 shares of the company’s stock worth $17,305,000 after acquiring an additional 117,523 shares during the last quarter. Principal Financial Group Inc. increased its stake in shares of Immunome by 222.3% in the 3rd quarter. Principal Financial Group Inc. now owns 1,104,938 shares of the company’s stock valued at $12,939,000 after buying an additional 762,147 shares during the period. Polar Capital Holdings Plc raised its stake in shares of Immunome by 5.9% during the third quarter. Polar Capital Holdings Plc now owns 1,058,776 shares of the company’s stock worth $12,398,000 after buying an additional 58,776 shares during the last quarter. Finally, Candriam S.C.A. grew its stake in shares of Immunome by 170.2% during the third quarter. Candriam S.C.A. now owns 859,527 shares of the company’s stock worth $10,065,000 after purchasing an additional 541,441 shares during the period. Institutional investors own 44.58% of the company’s stock.

Immunome Stock Performance

Shares of NASDAQ IMNM opened at $26.97 on Friday. Immunome has a 1 year low of $5.15 and a 1 year high of $27.23. The firm has a market cap of $2.47 billion, a P/E ratio of -9.14 and a beta of 2.32. The stock has a fifty day moving average price of $21.63 and a two-hundred day moving average price of $15.81.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Immunome had a negative return on equity of 76.50% and a negative net margin of 1,687.08%. On average, research analysts predict that Immunome will post -2.21 earnings per share for the current fiscal year.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.